Growth through Acquisition Devicare plans to acquire IP-6 International, signaling expansion into North America and potential cross-sell opportunities for urology digital therapeutics, nutraceutical integrations, and diagnostic tech with partners and customers in new markets.

Strategic Financing Recent loan from COFIDES and prior funding rounds indicate strong investor interest and financial backing, suggesting a viable path for co-investment or project financing discussions to accelerate market entry and deployment of digital therapies.

US Market Entry Past collaborations and fundraising tied to US market entry (Diem Labs partnership, Vaxdyn ecosystem) point to a readiness to engage US healthcare providers, distributors, and payers for urology digital solutions and diagnostic devices.

Digital Health Focus Devicare combines nutritional therapy with digital technologies for urology solutions, presenting opportunities to upsell SaaS platforms, telemedicine add-ons, data analytics services, and device-integrated digital therapeutics to clinics and hospital systems.

Moderate Scale, Global Opportunity With 11-50 employees and revenue in the lower to mid single digits, there is potential for channel partnerships, contract manufacturing, and regional distributors to accelerate scale while leveraging investors and partnerships to expand reach.